Loading...
•
Sep 30, 2025
Bruker Q3 2025 Earnings Report
Bruker posted a net loss and lower revenue in Q3 2025, as academic and research demand remained soft.
Key Takeaways
Bruker reported a modest decline in revenue and a GAAP net loss for Q3 2025, driven by earlier market weakness and impairment charges, though non-GAAP earnings exceeded expectations.
Revenue for Q3 2025 declined to $860.5M, down slightly year-over-year.
GAAP diluted EPS was $(0.41), while non-GAAP EPS came in at $0.45.
Net loss reached $62.4M due to impairment and restructuring charges.
Bookings improved in the academic, biopharma, and applied markets.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Bruker lowered its FY2025 guidance due to earlier market softness and EPS dilution, but expects margin expansion in 2026 driven by cost-savings initiatives.
Positive Outlook
- Improved bookings in academic and biopharma markets
- Sequential earnings improvement from Q2
- Strong customer reception to spatial biology and proteomics launches
- Foreign currency expected to provide a revenue tailwind
- Cost-saving initiatives on track to meet high end of $120M target
Challenges Ahead
- Lower FY2025 EPS guidance
- Organic revenue expected to decline 4–5%
- Impairment charges impacted Q3 results
- Restructuring charges also weighed on earnings
- Ongoing weakness in academic/research instrument demand
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...